InterVenn Stock
InterVenn Biosciences identifies, quantifies, and classifies Glycoproteomic and other PTM signals found in human blood and tissue.
Sign up today and learn more about InterVenn Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About InterVenn Stock
InterVenn focuses on the identification, quantification, and classification of Glycoproteomic and other PTM signals found in human blood and tissue for biomarker and target discovery. It specializes in the fields of biotechnology and life science. The company's VISTA is the first commercially available platform that can assess (serum or plasma) protein glycosylation in a site-specific manner, across thousands of peptides and glycopeptides. It was founded in 2017 and headquartered in Redwood City, California.
Investors
Anzu Partners
Oriza Ventures
Amplify Partners
Genoa Ventures
True Ventures
Opendoor, Zymergen, Fitbit, Automattic, Handshake, InterVenn, Personal Capital, Madison Reed, Namely, 3D Robotics
Funding History
| December 2018 | $9.4M |
|---|---|
| July 2020 | $33.7M |
| November 2020 | $34.0M |
| August 2021 | $201M |
Management
Scientific Co-Founder
Carolyn Bertozzi
Co-Founder and CEO
Aldo Carrascoso
Scientific Co-Founder
Carlito Lebrilla
SVP of QA, RA and Customer Excellence
Katherine Dalao
General Manager - Malaysia / VP Business Development
Fadzhairi Jabar
Chief Financial Officer
Brian Hogan
COO
Erwin Estigarribia
Country Manager
Axel Kornerup
Board of Directors
Adam D'Augelli
Investor
Sunil Dhaliwal
Board of Directors
Jenny Rooke
Advisor
Ryan Bethencourt
Senior Director of Pre-clinical R&D
Xin Cong
InterVenn Distinguished Scientist
Klaus Lindpaintner
Board Member
David Michael
Chief Medical Officer
Tillman Pearce
Director
Kenan Pandza
CBO
John Leite
Chief Data Officer
Dan Serie
VP, Clinical Development
Kaitlynn Moser
Press
patents - Apr, 14 2024
Diagnosis of colorectal cancer using targeted quantification of site-specific …patents - Apr, 14 2024
De novo glycopeptide sequencingpatents - Apr, 14 2024
Sample preparation for glycoproteomic analysis that includes diagnosis of …patents - Apr, 14 2024
Identification and use of glycopeptides as biomarkers for diagnosis and …patents - Apr, 14 2024
Biomarkers for determining a cancer disease state, response to immuno-oncology, …EquityZen Recognized As:
